tirzepatide obesity trial non-diabetic A 3-year study of in participants with and prediabetes showed substantial and sustained weight reduction and decreased risk of progression to diabetes with tirzepatide, as compared with placebo. Full SURMOUNT-1 surmount-1 trial tirzepatide non-diabetic obesity
Pay in 4 interest-free payments of $5.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17


























